Genetic testing that gives you insights into how your patient's genes may influence how they metabolize and respond to specific medications.
myDNA Psychotropic is a pharmacogenomic (PGx) test that analyzes your patient’s DNA for genetic variations deemed clinically significant.
The myDNA test results provide clinicians with information concerning drug metabolism and plasma concentrations (drug exposure) as well as the potential for altered clinical effects. This information may help you predict your patient’s response when selecting a medication.
A recent meta-analysis has shown that patients who received pharmacogenomic-guided antidepressant treatment were more likely to achieve symptom remission compared to patients without pharmacogenomic-guided treatment.⁽²⁾
Peer-reviewed pharmacogenomic guidelines, by international experts, offer clinically actionable recommendations on specific gene-drug interactions covering many commonly prescribed psychotropic medications.⁽³⁻⁵⁾
The myDNA Psychotropic PGx report is written by clinicians for clinicians to improve the actionability of PGx results.
Patients with a current or past history of experiencing medication side effects.
Patients experiencing suboptimal response to medications.
Our clinical team includes pharmacologists, molecular and clinical geneticists, researchers, and genetic counselors.
Collectively we’ve researched and referenced 1000s of global peer-reviewed studies to ensure that the insights and recommendations we provide are only those with the most substantial evidence and references.
Over 10,000 clinicians have used myDNA’s PGx service
Over 100,000 patients have taken a myDNA PGx test
CLIA and CAP-accredited laboratory
10+ years of experience processing genetic samples
1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
2. Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2018;20(1):37-47.
3. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-34.
4. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2016.
5. The Dutch Pharmacogenetics Working Group (DPWG) [Accessed 16 October, 2021]. Available from: https://www.knmp.nl/downloads/farmacogenetica-engels-recommendation-tekst.pdf.